Literature DB >> 6978216

Lymphocyte subpopulations and reactivity to mitogens in patients with scleroderma.

M Baron, E C Keystone, D D Gladman, P Lee, L Poplonski.   

Abstract

T lymphocyte subpopulations were studied in 40 patients with scleroderma (PSS), 26 of whom were studied simultaneously for lymphoproliferative responses to phytohaemagglutinin (PHA), concanavalin A (Con A) and pokeweed mitogen (PWM). PSS patients exhibited a reduction relative to 42 age- and sex-matched controls in the absolute number and percentage of early E rosettes, late E rosettes and E rosettes formed with aminoethylisothiouronium bromide (AET) treated sheep red blood cells. There was no difference between patients and controls in the proportions of B lymphocytes. PSS patients exhibited normal lymphocyte transformation responses to PHA and ConA and an augmented response to PWM. The mitogen responses did not correlate with the absolute number or percentage of lymphocytes or T and B lymphocyte subpopulations. No correlation was observed between any immunological variable studied and the extent of skin or organ involvement, disease duration or therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6978216      PMCID: PMC1536331     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Thymus-dependent (T) lymphocyte deficiency in progressive systemic sclerosis.

Authors:  P Hughes; S Holt; N R Rowell; J Dodd
Journal:  Br J Dermatol       Date:  1976-11       Impact factor: 9.302

2.  Cellular infiltrates in scleroderma skin.

Authors:  R Fleischmajer; J S Perlish; J R Reeves
Journal:  Arthritis Rheum       Date:  1977-05

3.  Leukocyte migration inhibition in progressive systemic sclerosis.

Authors:  P Hughes; S Holt; N R Rowell
Journal:  Br J Dermatol       Date:  1974-07       Impact factor: 9.302

4.  Immunological aspects of systemic sclerosis in vitro activity of lymphocytes from patients with the disorder.

Authors:  S Currie; M Saunders; M Knowles
Journal:  Br J Dermatol       Date:  1971-05       Impact factor: 9.302

5.  Human blood L lymphocytes in patients with active systemic lupus erythematosus, rheumatoid arthritis and scleroderma: a comparison with T and B cells.

Authors:  D A Horwitz; K Juul-Nielsen
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

6.  The relationship of defective cell-mediated immunity to visceral disease in systemic sclerosis.

Authors:  P Hughes; S Holt; N R Rowell; I D Allonby; K Janis; J K Dodd
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

7.  Lymphocyte reactivity to mitogens in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma.

Authors:  D A Horwitz; M A Garrett
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

8.  Subpopulations of human T lymphocytes. IX. Imbalance of T cell subpopulations in patients with progressive systemic sclerosis.

Authors:  S Gupta; A N Malaviya; P Rajagopalan; R A Good
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

9.  Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis.

Authors:  J M Stuart; A E Postlethwaite; A H Kang
Journal:  J Lab Clin Med       Date:  1976-10

10.  Cellular immunity in progressive systemic sclerosis (scleroderma).

Authors:  A Winkelstein; G P Rodnan; J D Heilman
Journal:  Ann Rheum Dis       Date:  1972-03       Impact factor: 19.103

View more
  8 in total

1.  Aberrations in lymphocyte subpopulations and function during psychological stress.

Authors:  B Dorian; P Garfinkel; G Brown; A Shore; D Gladman; E Keystone
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

2.  Detection of antilymphocyte antibodies in patients with scleroderma using three different techniques.

Authors:  M T Labro; A Perianin; M F Kahn
Journal:  Clin Rheumatol       Date:  1984-12       Impact factor: 2.980

3.  T-cell imbalance in progressive systemic sclerosis defined by monoclonal antibodies.

Authors:  A L Claudy; J C Le Petit; H Barthelemy; F Garcier
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

4.  Defective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis.

Authors:  A Kahan; A Kahan; C J Menkes; B Amor
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

5.  Invasive aspergillosis in a "healthy" patient.

Authors:  K J Ascah; R H Hyland; M A Hutcheon; S J Urbanski; W Pruzanski; E L St Louis; D P Jones; E C Keystone
Journal:  Can Med Assoc J       Date:  1984-08-15       Impact factor: 8.262

6.  Abnormal monocyte cytotoxicity and cyclic-AMP levels in systemic sclerosis.

Authors:  T Herlin; J Eggert; K Kragballe; H Zachariae
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

7.  T lymphocyte subset abnormalities and HLA antigens in scleroderma (systemic sclerosis).

Authors:  A J Barnett; B D Tait; M A Barnett; B H Toh
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

8.  Immunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies.

Authors:  E C Keystone; C Lau; D D Gladman; S Wilkinson; P Lee; A Shore
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.